Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Retraction Note

Retraction Note: The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells

Authors: Neil D Jelly, Issam I Hussain, Jennifer Eremin, Oleg Eremin, Mohamed El-Sheemy

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Excerpt

This article has been retracted [1] by the authors because errors were noted in the methodology employed in the experiments which invalidate the results reported. The authors apologise for any inconvenience caused. …
Literature
1.
Jelly ND, Hussain II, Eremin J, Eremin O, El-Sheemy M: The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells. Cancer Cell Int. 2012, 12: 21-10.1186/1475-2867-12-21.PubMedCentralCrossRefPubMed
Metadata
Title
Retraction Note: The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells
Authors
Neil D Jelly
Issam I Hussain
Jennifer Eremin
Oleg Eremin
Mohamed El-Sheemy
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-96

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue

Primary research

Expression pattern of the apoptosis-stimulating protein of p53 family in p53+ human breast cancer cell lines

Primary research

Si-RNA mediated knockdown of CELF1 gene suppressed the proliferation of human lung cancer cells

Primary research

Influence on the behavior of lung cancer H1299 cells by silencing SLC35F2 expression

Primary research

X-ray irradiation promotes apoptosis of hippocampal neurons through up-regulation of Cdk5 and p25

Primary research

FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia

Primary research

Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits